Association between bisphosphonate use and COVID-19 related outcomes
eLife · 03.08.2023 · 12
DOI: 10.7554/elife.79548 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 03.08.2023. Verfasst von Jeffrey Thompson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cerner Enviza, Malvern, United States. Hauptthemen laut MEDLINE: COVID-19, Respiratory Tract Infections, Bronchitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Institute, NIAID NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Background
Although there are several efficacious vaccines against COVID-19, vaccination rates in many regions around the world remain insufficient to prevent continued high disease burden and emergence of viral variants. Repurposing of existing therapeutics that prevent or mitigate severe COVID-19 could help to address these challenges. The objective of this study was to determine whether prior use of bisphosphonates is associated with reduced incidence and/or severity of COVID-19.
Methods
A retrospective cohort study utilizing payer-complete health insurance claims data from 8,239,790 patients with continuous medical and prescription insurance January 1, 2019 to June 30, 2020 was performed. The primary exposure of interest was use of any bisphosphonate from January 1, 2019 to February 29, 2020. Bisphosphonate users were identified as patients having at least one bisphosphonate claim during this period, who were then 1:1 propensity score-matched to bisphosphonate non-users by age, gender, insurance type, primary-care-provider visit in 2019, and comorbidity burden. Main outcomes of interest included: (a) any testing for SARS-CoV-2 infection; (b) COVID-19 diagnosis; and (c) hospitalization with a COVID-19 diagnosis between March 1, 2020 and June 30, 2020. Multiple sensitivity analyses were also performed to assess core study outcomes amongst more restrictive matches between BP users/non-users, as well as assessing the relationship between BP-use and other respiratory infections (pneumonia, acute bronchitis) both during the same study period as well as before the COVID outbreak.
Results
A total of 7,906,603 patients for whom continuous medical and prescription insurance information was available were selected. A total of 450,366 bisphosphonate users were identified and 1:1 propensity score-matched to bisphosphonate non-users. Bisphosphonate users had lower odds ratios (OR) of testing for SARS-CoV-2 infection (OR = 0.22; 95%CI:0.21–0.23; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cerner Enviza, Malvern, United States.
- Dept. of Immunology, Harvard Medical School, Boston, United States.
- Institute of General Practice and Family Medicine, University Hospital of Ludwig Maximilians-University Munich, Munich, Germany.
- Center of Integrated Protein Science Munich and Division of Clinical Pharmacology, University Hospital, LMU Munich, Germany, Munich, Germany.
ORCID-Profile: Stefan Endres, Ulrich H von Andrian
Förderung
- Cancer Research Institute
- NIAID NIH HHS
- NIAMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- MassCPR
Zitieren
APA
Thompson, J., Wang, Y., Dreischulte, T., Barreiro, O., Gonzalez, R. J., Hanč, P., Matysiak, C., Neely, H. R., Rottenkolber, M., Haskell, T., Endres, S., & von Andrian, U. H. (2023). Association between bisphosphonate use and COVID-19 related outcomes. eLife, 12. https://doi.org/10.7554/elife.79548
Vancouver
Thompson J, Wang Y, Dreischulte T, Barreiro O, Gonzalez RJ, Hanč P, et al. Association between bisphosphonate use and COVID-19 related outcomes. eLife. 2023;12. doi:10.7554/elife.79548
BibTeX
@article{Thompson2023,
author = {Thompson, Jeffrey and Wang, Yidi and Dreischulte, Tobias and Barreiro, Olga and Gonzalez, Rodrigo J and Hanč, Pavel and Matysiak, Colette and Neely, Harold R and Rottenkolber, Marietta and Haskell, Thomas and Endres, Stefan and von Andrian, Ulrich H},
title = {Association between bisphosphonate use and COVID-19 related outcomes},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.79548}
}
EUVIMED